The global Hypopituitarism Diagnostics Market is anticipated to reach a market value of US$ 250 million in 2023 and to reach US$ 447.41 million by 2033, at a CAGR of 6%. Between 2017 and 2022, the market for hypopituitarism diagnostics experienced a 4% CAGR.
The significant link between hypopituitarism and a lack of growth hormone is anticipated to drive market expansion. Human growth hormone aids in promoting growth, reproduction, and regeneration. Hormone deficiency is a severe problem for both children and adults, which is driving more and more study and development. For instance, in October 2019, Pfizer Inc. and its partner OPKO Health Inc. stated that the primary endpoint of their Phase III research testing Somatrogon’s non-inferiority to daily somatropin in pre-pubertal children using human growth hormone had been met.
Request a report sample to gain comprehensive insights @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16373
Additionally, a number of start-ups are introducing new treatments for this uncommon illness. One such company is Eli, a Canadian FemTech start-up that is working on a saliva-based at-home gadget that can measure daily hormone variations and an app that offers insights specific to each user’s individual profile. Despite being fundamental to women’s reproductive and general health, hormones are still largely unknown. Eli opens this box, giving women access to their daily hormonal data. The company creates an at-home device that measures hormone variations in saliva as well as an app that provides women with the knowledge they need to take control of their daily and long-term health decisions.
Key Takeaways from the Market Study:
- From 2018-2022, the hypopituitarism diagnostics market grew at a CAGR of 4%
- The global hypopituitarism diagnostics market is expected to grow with a 6% CAGR during 2023-2033.
- As of 2033, the Hypopituitarism Diagnostics Market is expected to reach US$ 447.41 Million
- According to the FMI analysis, hospitals account for the largest market share
- North America is expected to possess 25% market share for the Hypopituitarism Diagnostics market
- Asia Pacific is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
Reach out to our analyst for prompt assistance with your questions @ https://www.futuremarketinsights.com/ask-question/rep-gb-16373
“Due to the hectic life patterns of the citizens working in cities, there has been an observed increase in stress and sleeplessness. These challenges are emerging as the main factor for the deteriorating health in the urban population by disrupting the hormonal balance in the human body,” says an FMI analyst.
Market Competition:
Key players in the Hypopituitarism Diagnostics market are Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories Inc., Danaher Corporation, Siemens AG, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, and Thermo Fisher Scientific.
- In January 2022, Pfizer Inc. and OPKO Health, Inc. announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for somatrogon. Somatrogon is an investigational once-weekly long-acting recombinant human growth hormone for the treatment of growth hormone deficiency (GHD) in pediatric patients. Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward.
More Insights Available:
FMI, in its new offering, presents an unbiased analysis of the global hypopituitarism diagnostics market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023-2033.
The study reveals essential insights on the basis of Test Type (Hormone Stimulation Tests, MRI or CT Scan, Visual Field Check, Insulin Tolerance Test), End User (Academic Research Institutes, Hospitals, Specialty Clinics, Others) & region.
Customize Your Knowledge: Unlock Targeted Insights to Drive Growth in the Market for Hypopituitarism Diagnostics @ https://www.futuremarketinsights.com/customization-available/rep-gb-16373
Key Companies Profiled:
- Abbott Laboratories
- Becton, Dickinson, and Company
- BioMerieux
- Bio-Rad Laboratories Inc.
- Danaher Corporation
- Siemens AG
- Hologic Inc.
- Qiagen NV
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific
Key Segments Profiled in the Hypopituitarism Diagnostics Industry Survey
By Test Type:
- Hormone Stimulation Tests
- MRI or CT Scan
- Visual Field Check
- Insulin Tolerance Test
By End User:
- Specialty Clinics
- Hospitals
- Academic Research Institutes
- Others
Act Now to Explore In-Depth Market Analysis: Get Exclusive Purchase Now to Access @ https://www.futuremarketinsights.com/checkout/16373
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
